Paul Saenger

Long acting growth hormone (LAGH), an update

Margaret Steiner Grillo, Jacklyn Frank, Paul Saenger, 2023, Frontiers in Pediatrics.

Seven Years of Safety and Efficacy of the Recombinant Human Growth Hormone Omnitrope® in the Treatment of Growth Hormone Deficient Children: Results of a Phase III Study

Y. Le Bouc, P. Saenger, F. Péter, 2009, Hormone Research in Paediatrics.

Transient congenital hypoparathyroidism: resolution and recurrence in chromosome 22q11 deletion.

P. Saenger, J. Dimartino-Nardi, F. Greig, 1996, The Journal of pediatrics.

Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature. Genentech Collaborative Study Group.

J. Frane, P. Saenger, K. Attie, 1998, The Journal of clinical endocrinology and metabolism.

The effect of luteinizing hormone-releasing hormone analog for central precocious puberty on growth hormone (GH) and GH-binding protein.

P. Saenger, J. Dimartino-Nardi, R. Wu, 1994, The Journal of clinical endocrinology and metabolism.

Response to growth hormone in children with idiopathic short stature

L. Plotnick, J. Frane, P. Saenger, 1990 .

A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency.

B. Silverman, P. Saenger, K. Attie, 2001, The Journal of clinical endocrinology and metabolism.

Growth response of children with non-growth-hormone deficiency and marked short stature during three years of growth hormone therapy.

L. Plotnick, S. Chernausek, R. Hintz, 1993, The Journal of pediatrics.

Pseudotumor cerebri in an infant after L-thyroxine therapy for transient neonatal hypothyroidism.

P. Saenger, J. Dimartino-Nardi, B. Linder, 1997, The Journal of pediatrics.